Charles River Laboratories International, Inc. (NYSE:CRL) Stock Position Decreased by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 8.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,568 shares of the medical research company's stock after selling 2,196 shares during the period. Vestmark Advisory Solutions Inc.'s holdings in Charles River Laboratories International were worth $4,351,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in CRL. Virtu Financial LLC purchased a new position in Charles River Laboratories International in the 3rd quarter valued at approximately $601,000. JPMorgan Chase & Co. grew its holdings in Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after purchasing an additional 85,759 shares during the last quarter. State Street Corp raised its stake in shares of Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock worth $419,601,000 after buying an additional 41,421 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Charles River Laboratories International by 3.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock worth $22,060,000 after buying an additional 3,714 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after acquiring an additional 3,268 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 4,400 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO James C. Foster purchased 6,075 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CRL. Robert W. Baird reduced their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a research report on Monday, March 3rd. UBS Group reissued a "neutral" rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Finally, CLSA downgraded shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 target price for the company. in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $198.36.

Charles River Laboratories International Trading Down 0.4 %

Shares of CRL traded down $0.79 during mid-day trading on Monday, reaching $175.13. The company had a trading volume of 1,516,878 shares, compared to its average volume of 703,174. The stock has a market cap of $8.96 billion, a price-to-earnings ratio of 1,167.55, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a fifty day simple moving average of $169.15 and a 200-day simple moving average of $185.63. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $274.77.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period last year, the business posted $2.46 EPS. The company's quarterly revenue was down 1.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).